Article thumbnail

Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer

By Evelina Miele, Gian Paolo Spinelli, Ermanno Miele, Federica Tomao and Silverio Tomao


Breast cancer is the most common type of malignancy diagnosed in women. In the metastatic setting this disease is still uncurable. Taxanes represent an important class of antitumor agents which have proven to be fundamental in the treatment of advanced and early-stage breast cancer, but the clinical advances of taxanes have been limited by their highly hydrophobic molecular status. To overcome this poor water solubility, lipid-based solvents have been used as a vehicle, and new systemic formulations have been developed, mostly for paclitaxel, which are Cremophor-free and increase the circulation time of the drug. ABI-007 is a novel, albumin-bound, 130-nm particle formulation of paclitaxel, free from any kind of solvent. It has been demonstrated to be superior to an equitoxic dose of standard paclitaxel with a significantly lower incidence of toxicities in a large, international, randomized phase III trial. The availability of new drugs, such as Abraxane®, in association with other traditional and non-traditional drugs (new antineoplastic agents and targeted molecules), will give the oncologist many different effective treatment options for patients in this setting

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2007). 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain. Clin Cancer Res.
  2. (2005). Abraxis Oncology, a Division of American Pharmaceutical Partners, Inc;
  3. (2005). Acute toxicity of intravenously administered microfabricated silicon dioxide drug delivery particles in mice: preliminary fi ndings. Drugs R D.
  4. (2001). Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein. Am J Physiol Lung Cell Mol Physiol.
  5. An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells.
  6. Biological applications of dendrimers.
  7. (2005). Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer.
  8. (2008). Cancer Network, Clinical Practice Guidelines in Oncology: Breast Cancer v2,
  9. (2008). Cancer statistics,
  10. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction.
  11. Caveolin regulation of endothelial function.
  12. (2005). Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res.
  13. (1997). Corticosteroids signifi cantly delay the onset of docetaxel-induced fl uid retention: fi nal results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol.
  14. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation.
  15. (1999). Cremophor elmediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res.
  16. (2007). Dendrimer-modifi ed magnetic nanoparticles enhance effi ciency of gene delivery system. Cancer Res.
  17. (2007). Electrostatic ligand coatings of nanoparticles enable ligand-specifi c gene delivery to human primary cells. Nano Lett.
  18. (2002). Engineering tumor-targeted gadolinium hexanedione nanoparticles for potential application in neutron capture therapy. Bioconjug Chem.
  19. (2002). Evidence of a novel transporter mechanism for a Cremophorfree, protein-engineered paclitaxel (ABI-007) and enhanced in vivo antitumor activity in an MX-1 human breast tumor xenograft model.
  20. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer:
  21. Fatal outcome of a hypersensitivity reaction to paclitaxel: A critical review of premedication regimens.
  22. (1997). Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway.
  23. High affi nity binding of paclitaxel to human serum albumin.
  24. (1977). Histamine release in dogs by Cremophor EL and its derivatives: Oxethylated oleic acid is the most effective constituent. Agents Actions.
  25. (1990). Hypersensitivity reactions from Taxol. J Clin Oncol.
  26. (2005). Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett.
  27. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
  28. (2006). Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res.
  29. (2003). Injection Concentrate: Package Insert.
  30. (2000). Interaction of Taxol with human serum albumin. Biochim Biophys Acta.
  31. Liposomal anthracyclines in metastatic breast cancer: clinical update.
  32. Liposomal anticancer therapy: pharmacokinetic and clinical aspects.
  33. (2008). Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol.
  34. Multicenter phase II trial of ABI-007, an albumin- bound paclitaxel, in women with metastatic breast cancer.
  35. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance.
  36. (2008). Nanotechnology for breast cancer therapy. Biomed Microdevices.
  37. (1995). Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.
  38. Overview of adjuvant systemic therapy in early stage breast cancer.
  39. (1993). Overview of paclitaxel safety.
  40. (1994). Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.
  41. (2003). Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet.
  42. (2002). Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res.
  43. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
  44. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
  45. Practical aspects of weekly docetaxel administration schedules.
  46. Preclinical pharmacology of docetaxel.
  47. Promotion of microtubule assembly in vitro by Taxol.
  48. (2008). Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev.
  49. (2003). Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol.
  50. (2007). Quantum rod bioconjugates as targeted probes for confocal and two-photon fl uorescence imaging of cancer cells. Nano Lett.
  51. (1999). Reversible ligand binding to human serum albumin: Theoretical and clinical aspects. Dan Med Bull.
  52. (2001). Role of formulation vehicles in taxane pharmacology. Invest New Drugs.
  53. Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fl uid retention: fi nal results of a randomized trial of the EORTC investigational drug branch for breast cancer (IDBBC). Eur J Cancer. 1995;31A suppl 5:S75.
  54. Synthesis and characterization of silica-embedded iron oxide nanoparticles for magnetic resonance imaging.
  55. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
  56. (1999). Taxanes in combined-modality therapy for solid tumors. Oncology
  57. (1980). Taxol stabilizes microtubules in mouse fi broblast cells.
  58. Taxol: a history of pharmaceutical development and current pharmaceutical concerns.
  59. Taxol: a novel investigational antimicrotubule agent.
  60. (2003). Taxol® (paclitaxel) injection [package insert].
  61. The curability of breast cancer and the treatment of advanced disease.
  62. (2003). The dawning era of polymer therapeutics. Nat Rev Drug Discov.
  63. (2003). The embedding of meta-tetra(hydroxyphenyl)-chlorin into silica nanoparticle platforms for photodynamic therapy and their singlet oxygen production and pH-dependent optical properties. Photochem Photobiol.
  64. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul.
  65. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.
  66. The taxanes: An update.
  67. (1986). Therapeutic response to Taxol of six human tumors xenografted into nude mice. Cancer Chemother Pharmacol.
  68. (2004). Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev.
  69. (2003). Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.